First Analysis
http://www.firstanalysis.com/index.asp?PID=16First Analysis is an investment organization specializing in private equity, venture capital, investment banking, and equity research. The sectors in the firm’s coverage universe include outsourced services, IT products and services, and chemistry-enabled businesses. First Analysis was founded in 1981.
View Older Stories View More Recent Stories
-
sticky.io Announces Growth Equity Investment Following Recent Rebrand
-
Bayer to Highlight Clinical Data on Vitrakvi® (larotrectinib) and Research on Investigational AhR Inhibitor at AACR 2020 Virtual Meeting
-
VIDA Completes Second Close Of Round C Financing
-
Tabula Rasa HealthCare® Names Frank Sparacino SVP Investor Relations and Corporate Development
-
Tabula Rasa HealthCare® Names Frank Sparacino SVP Investor Relations and Corporate Development
-
Independent Third-Party Analyst Gives UC Asset “Buy” Rating with Target Price at $5.50 per Share
-
World's First Analysis of Collaboration Platform Microsoft Teams Released by SWOOP Analytics
-
VIDA Announces Series C Financing To Accelerate Access To AI-Powered Lung Imaging Analysis
-
Amid Coronavirus Outbreak, New Research Reveals the Makeup of the U.S. State and Local Public Health Workforce
-
Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities
-
Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer
-
UPDATE: First Analysis Downgrades CryoLife (CRY) to Outperform
-
First Analysis Upgrades CyberArk Software (CYBR) to Strong Buy
-
First Analysis Starts Zuora Inc. (ZUO) at Outperform
-
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
-
First Analysis Upgrades Anika Therapeutics (ANIk) to Strong Buy
-
Premier Inc. Analysis: Complications & Common Chronic Conditions Increase Hospitals’ Childbirth Costs by 20 Percent or More
-
First Analysis Downgrades CalAmp Corp. (CAMP) to Neutral
-
Pre-Open Movers 12/10: (ASNA) (GNW) (SFIX) Higher; (CONN) (SCYX) (FRAN) Lower (more...)
-
First Analysis Upgrades Avid Bioservices (CDMO) to Strong Buy
-
First Analysis Downgrades Instructure, Inc. (INST) to Neutral Following Acquisition
-
AVEO Oncology (AVEO) Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in RCC
-
AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
-
Astellas Presents New Data on XOSPATA® (gilteritinib) in FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia at the 2019 American Society of Hematology Annual Meeting
-
The Global Beauty Community Gathers at Cosmoprof Asia 2019
-
AbbVie (ABBV) to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at ASH
-
AbbVie to Present Latest Clinical Research in the Treatment of Leukemias, Lymphomas and Other Blood Cancers at 2019 ASH Annual Meeting
-
AVEO Oncology (AVEO) Highlights Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in RCC
-
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
-
First Analysis Starts Smartsheet Inc. (SMAR) at Outperform
-
PathAI and Gilead Show AI-Powered Pathology Research Models Accurately Interpret Liver Histology in Patients with NASH at AASLD 2019
-
First Analysis Upgrades Quotient Technology (QUOT) to Strong Buy
-
Takeda's (TAK) Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
-
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
-
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
-
Octapharma’s fibryga® Receives European Label Extension to Treat Acquired Fibrinogen Deficiency (AFD)
-
First Analysis Upgrades Repligen (RGEN) to Strong Buy
-
First Analysis Starts Upwork Inc. (UPWK) at Outperform
-
First Analysis Upgrades SPS Commerce (SPSC) to Strong Buy
-
First Analysis Downgrades LeMaitre Vascular (LMAT) to Outperform
-
First Analysis Upgrades Alarm.com (ALRM) to Strong Buy
-
First Analysis Upgrades LeMaitre Vascular (LMAT) to Strong Buy
-
Citius Reaches First Interim Analysis Milestone for Mino-Lok® Pivotal Trial
-
First Analysis Starts BlackLine (BL) at Outperform
-
Not Addressing Poverty is Costing Ontario up to $33 Billion Per Year
-
Media Advisory: Feed Ontario (formerly the Ontario Association of Food Banks) to release a new study on the Cost of Poverty in Ontario on October 1st, 2019
-
First Analysis Downgrades Anika Therapeutics (ANIK) to Outperform
-
First Analysis Upgrades LiveRamp Holdings Inc. (RAMP) to Strong Buy
-
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
-
Delivery-Related Maternal Mortalities in the Hospital Decreased by 24% from 2008-2018

